Newsletter | July 14, 2021

07.14.21 -- Stealth Mode: What To Know And Do

Coming Out Of Stealth Mode: What To Know And Do

Five CEOs discuss their experiences with stealth mode transitions. They address when and how a company should turn away from that introspective state and show itself to the world.

From Fusion Energy To Med Device … To Drug Developer?

TAE Life Sciences wanted to create a combination product that brought together its neutron beam with a drug that delivers boron to cancer cells. But the company didn’t want to be in a position where it relied on another company for the drug needed.

Hiring For Talent, Not Geography

It is more important to build a team of talented individuals, united around a common goal, than to narrow in on the location where those people are based.

First-Time CEOs: Firsthand Tales Of The Good, The Bad, And The Ugly

Since the CEO position comes with such high expectations and stress, we thought it would be interesting to speak with three first-time CEOs to hear their tales of the good, the bad, and the ugly. In this executive virtual roundtable (EVR), perspectives are provided by Roger Crystal, CEO, Opiant Pharmaceuticals, Frank Lee, CEO, Forma Therapeutics, and Ivana Magovcevic-Liebisch, Ph.D., J.D., CEO, Vigil Neuroscience.

Web-Exclusive Content
The FDA And The Chemistry, Manufacturing, And Controls (CMC) Goalposts: CMC Should Accelerate, Not Curb, Gene Therapy Progress
When it comes to CMCs, is the FDA cracking down on the industry more harshly than expected?
July 2021 Digital Edition

Inside you will find more on:

  • A Look At Travere's CEO
  • AI In Pharma
  • Clinical Trials
  • Companies To Watch

View the digital edition.

Contribute To Life Science Leader
Article Submission Guidelines

Think you have a good idea for an article that Life Science Leader readers would find valuable? Read these guidelines first before submitting your idea or your article to our editorial director.